CoChat
Sign Up
Cited by 198Obsessive-Compulsive Spectrum DisordersSchizophrenia research and treatmentPsychoanalysis and Psychopathology Research

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Risperidone augmentation in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study

Open access
Hollander, Eric, Rossi, Nicolò Baldini, Sood, Erica, Pallanti, Stefano·2003·The International Journal of Neuropsychopharmacology
DOI 10.1017/s1461145703003730
Open this paper in CoChat — free accountOpen PDF

Abstract

This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive-compulsive disorder (OCD) (failure of at least two SRI trials). Sixteen adult treatment-resistant OCD patients were randomly assigned to augmentation with 8 wk of either risperidone (n=10) (0.5-3.0 mg/d) or placebo (n=6) following at least 12 wk of SRI treatment. Four patients on risperidone (40%) and none (0%) on placebo were responders with both a Clinical Global Impression - Improvement (CGI-I) score of 1 or 2 and a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) decrease >/=25%. Risperidone was generally well tolerated: there were 3 dropouts, 1 on risperidone and 2 on placebo. Better Y-BOCS insight score at baseline significantly correlated with a greater CGI-I score at endpoint on risperidone augmentation. Risperidone may be an effective and well-tolerated augmentation strategy in treatment-resistant OCD subjects, but larger sample size studies are required to demonstrate this.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145703003730

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

Sorted by citations

Items 101–198 of 198

Related

See all

Metadata

Authors
Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • University of Pisa (IT)
  • University of Florence (IT)
Corresponding author
Hollander, Eric
ORCID
Venue
The International Journal of Neuropsychopharmacology
Publisher
Oxford University Press (OUP)
Published
2003-12
Volume
6
Issue
4
Pages
397-401
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
DOI
10.1017/s1461145703003730
OpenAlex
W1966161934
Cited by
197
References
19
Citations by year
2026: 2 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 7 · 2018: 8 · 2017: 7 · 2016: 5 · 2015: 16 · 2014: 10 · 2013: 7 · 2012: 10
FWCI
17.49
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Funders
Janssen Pharmaceuticals
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
Keywords
risperidone, treatment-resistant OCD, augmentation therapy, serotonin reuptake inhibitors, antipsychotic augmentation, drug tolerability, treatment response, insight, Yale-Brown Obsessive Compulsive Scale, Clinical Global Impression Scale
MeSH terms
Adult, Ambulatory Care, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Personality Inventory, Antipsychotic Agents, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review